EQS-Adhoc: Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets
|
EQS-Ad-hoc: Eckert Ziegler Strahlen- und Medizintechnik AG / Key word(s): Strategic Company Decision
Berlin, 20 October 2023. The Supervisory Board of Eckert Ziegler AG (ISIN DE0005659700, SDAX) today has given its approval to the Executive Board to examine and prepare a split-off of up to 100 percent of the shares in the Pentixapharm AG (PTX). In accordance with IFRS 5, the Executive Board will report PTX as a discontinued operation in the 2023 annual financial statements. A separate decision will be taken at a later date on the specific start and the manner of the exit. In accordance with IFRS 5, the Executive Board will report PTX as a discontinued operation in the 2023 annual financial statements. PTX also includes Myelo Therapeutics GmbH.
Given the enormous growth forecast for active pharmaceutical ingredients, which is already reflected in the order intake, Eckert Ziegler intends to pool its financial resources to expand its global manufacturing capacities. Eckert Ziegler is thus concentrating on its core competencies in order to further expand its position as a leading supplier of radioisotopes for the production of radiopharmaceuticals. The forecast for the financial year 2023 remains unchanged. Contact: Eckert Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, 13125 Berlin, Germany Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com End of Inside Information
20-Oct-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Eckert Ziegler Strahlen- und Medizintechnik AG |
| Robert-Rössle-Str.10 | |
| 13125 Berlin | |
| Germany | |
| Phone: | +49 30 941084-138 |
| Fax: | +49 30 941084-112 |
| E-mail: | [email protected] |
| Internet: | www.ezag.de |
| ISIN: | DE0005659700 |
| WKN: | 565970 |
| Indices: | SDAX, |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1754139 |
| End of Announcement | EQS News Service |
|
|
1754139 20-Oct-2023 CET/CEST
Eckert & Ziegler Strahlen- und Medizintechnik AG Stock
€43.62
1.730%
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Eckert & Ziegler Strahlen- und Medizintechnik AG.
With a target price of 95 € there is potential for a 117.79% increase which would mean more than doubling the current price of 43.62 € for Eckert & Ziegler Strahlen- und Medizintechnik AG.
